Skip to main content
. Author manuscript; available in PMC: 2020 Sep 10.
Published in final edited form as: J Pathol. 2019 Nov 14;250(1):79–94. doi: 10.1002/path.5352

Figure 3. Inhibition of EZH2 suppresses TGF-β1/Smad3 and Notch1/Jagged-1 signaling pathway and inhibits phosphorylation of EGFR as well as Src in the fibrotic peritoneum.

Figure 3.

(A) Peritoneum tissue lysates were prepared and subjected to immunoblot analysis with antibodies against TGF-βRI, p-Smad3, Smad3, Smad7, or GAPDH. (B) Peritoneal tissue lysates were subjected to the determination of TGF-β1 levels by the ELISA. (C) Expression levels of TGF-βRI and p-Smad3 were quantified by densitometry and normalized respectively with GAPDH and Smad3. (D) Expression level of Smad7 was quantified by densitometry and normalized with GAPDH. (E) The prepared peritoneum tissue lysates were subjected to immunoblot analysis with antibodies against p-EGFR, EGFR, p-Src, Src, or GAPDH. These proteins were quantified by densitometry. (F) p-EGFR and p-Src levels were normalized with their total protein levels. (G) Peritoneum tissue lysates were prepared and subjected to immunoblot analysis with antibodies against Notch1, Jagged-1 or GAPDH. (H) Expression levels of Notch1 and Jagged-1 were quantified by densitometry and normalized with GAPDH. Data are represented as the mean ± S.E.M (n = 6). Means with different superscript letters are significantly different from one another (P< 0.05).